Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Fineline Cube Dec 22, 2025
Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Fineline Cube Dec 22, 2025
Company Drug

Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine

Fineline Cube Mar 7, 2023

US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from...

Policy / Regulatory

Sunshine Medical Procurement Platform Announces VBP Tender Results for Yangtze River Delta

Fineline Cube Mar 7, 2023

Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) platform has revealed the resultant winning bids and spare...

Company Deals

Neo Modulus Secures Series B Funding for Regenerative Medical Device Development

Fineline Cube Mar 7, 2023

Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised...

Company Drug

Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions

Fineline Cube Mar 7, 2023

Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity...

Policy / Regulatory R&D

Pudong New Area Grants Duty-Free Import Qualifications to Seven Companies

Fineline Cube Mar 7, 2023

Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the...

Company Drug

Harbour BioMed’s Batoclimab Shows Positive Results in gMG Phase III Trial

Fineline Cube Mar 7, 2023

Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...

Company Policy / Regulatory

BGI Group Subsidiaries Added to US Trade Blacklist by Commerce Department

Fineline Cube Mar 7, 2023

The US Department of Commerce (DOC)’s Bureau of Industry and Security (BIS) has added 37...

Company

Sanyou Biopharmaceuticals Expands Global Reach with New Cambridge Office

Fineline Cube Mar 6, 2023

Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is set to open a new...

Company Drug

Sanofi’s Dupixent Receives Priority Review for Prurigo Nodosa Treatment

Fineline Cube Mar 6, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status...

Policy / Regulatory

China’s Premier Li Keqiang Highlights Economic and Social Advances in Annual Report

Fineline Cube Mar 6, 2023

Premier Li Keqiang delivered his annual Government Work Report at the “Two Sessions” meeting, which...

Company Drug

Eli Lilly’s Retevmo Launched in China by Innovent Biologics

Fineline Cube Mar 6, 2023

Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese...

Company Deals

QL Biopharm Raises Series B Funding for Protein Drug Development

Fineline Cube Mar 6, 2023

QL Biopharm, a Beijing-based developer of Escherichia coli-based protein drugs, has reportedly raised RMB 100...

Company Drug

Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials

Fineline Cube Mar 6, 2023

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical...

Company Drug

Hengrui’s Adebrelimab Receives NMPA Approval for Lung Cancer Treatment

Fineline Cube Mar 6, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that it has received marketing approval from the...

Company Deals

Siyi Intelligence Raises Series A Funding for Neural Rehabilitation Solutions

Fineline Cube Mar 6, 2023

Siyi Intelligence, a developer of soft rehabilitation robots based in Shanghai, has reportedly raised close...

Company Drug

Sino Biopharmaceutical’s Bevacizumab Biosimilar Approved by NMPA

Fineline Cube Mar 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from the...

Company Drug

Mabwell’s 9MW3911 Monoclonal Antibody Accepted for NMPA Review

Fineline Cube Mar 6, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...

Company Drug

Venus Medtech Completes Patient Enrollment for Liwen RF Ablation System Study

Fineline Cube Mar 6, 2023

China-based Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced that all patients have been successfully...

Company Deals

PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices

Fineline Cube Mar 6, 2023

PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of...

Company Deals R&D

HKUST and PhIRDA Sign MoU to Establish Innovation Centers

Fineline Cube Mar 4, 2023

The Hong Kong University of Science and Technology (HKUST) and the China Pharmaceutical Innovation and...

Posts pagination

1 … 489 490 491 … 600

Recent updates

  • Novartis MSD Sanofi TrumpRx Deal Targets Medicaid Pricing
  • Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
  • Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
  • MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
  • Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Novartis MSD Sanofi TrumpRx Deal Targets Medicaid Pricing

Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.